The healthcare system, including Medicare, transitions from ICD-9 to ICD-10 as the medical code set for medical diagnoses and inpatient hospital procedures on October 1, 2015. One of our top priorities is to continue to make the process of ordering GeneSight as easy and efficient for you as possible. We are pleased to share that we are fully prepared for the conversion to ICD-10 on October 1. Please contact your Molecular Sales Consultant or contact our Customer Service Department for more information at 866.757.9204. Read more.
A new study published in Current Medical Research and Opinion demonstrated $1,036 in annual prescription savings per patient when healthcare providers used the GeneSight® combinatorial pharmacogenomic (CPGx) test results to guide treatment decisions compared with usual trial-and-error prescribing. CPGx is the evaluation of multiple genetic factors that influence an individual’s response to medications. Read more Read more.
GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests Retrospective Chart Review Also Showed GeneSight Results Can... Read more.
